<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="723">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377206</url>
  </required_header>
  <id_info>
    <org_study_id>PRTS13-CH / NICAD</org_study_id>
    <nct_id>NCT02377206</nct_id>
  </id_info>
  <brief_title>Neuroinflammation and Cognitive Decline in Alzheimer Disease</brief_title>
  <acronym>NICAD</acronym>
  <official_title>Neuroinflammation and Cognitive Decline in Alzheimer Disease (AD) : Pilot Study of Translocator Proteins Ligand PET Imaging With [18F]DPA-714</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the level of neuroinflammation in Alzheimer Disease&#xD;
      subject (mild to moderate) estimated with Binding Potential (BP) of [18F]DPA-714, and its&#xD;
      relationship with the kinetics of cognitive decline over a 24-month follow-up period (as&#xD;
      assessed by Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) and&#xD;
      Mini-Mental State Examination (MMSE) scores).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the level of neuroinflammation in Alzheimer Disease&#xD;
      subject (mild to moderate) estimated with Binding Potential (BP) of [18F]DPA-714 , and its&#xD;
      relationship with the kinetics of cognitive decline over a 24-month follow-up period (as&#xD;
      assessed by ADAS-Cog and MMSE scores).&#xD;
&#xD;
      (DPA-714 :&#xD;
      N,N-diethyl-2-[4-(2-fluoroethoxy)phenyl]-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-acetamide)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 6, 2016</start_date>
  <completion_date type="Actual">December 4, 2019</completion_date>
  <primary_completion_date type="Actual">December 4, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the neuroinflammation measured by fixing and layout of [18F]DPA-714 between 3 groups of patients : subjects suffering from Alzheimer disease light to mild stage, amnesiac MCI and patients suffering from isolated cognitive complaint</measure>
    <time_frame>inclusion and 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship passessment between [18F]DPA-714 fixing</measure>
    <time_frame>Inclusion and 34 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Alzheimer Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alzheimer Disease People ADAS-Cog evaluation PET imaging with [18F]DPA-714</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ADAS-Cog evaluation</intervention_name>
    <description>[18F]DPA-714 PET imaging</description>
    <arm_group_label>Alzheimer Disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Age more than 50 years (included)&#xD;
&#xD;
          -  necessary knowledge of French (write and oral) to do neuropsychological tests&#xD;
&#xD;
          -  Study level upper (or equal) than 7 years (considering first year of grammar-school as&#xD;
             start)&#xD;
&#xD;
          -  People with Alzheimer Disease defined as National Institute of Neurological and&#xD;
             Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related&#xD;
             Disorders Association (ADRDA) standards : Light to mild AD defined by Mini-Mental&#xD;
             State Examination (MMSE) score between 15 and 25 (included)&#xD;
&#xD;
          -  Social security affiliation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MMSE score lower than 15 and upper or equal to 26&#xD;
&#xD;
          -  Evolutive disease which could possibly had consequences on central nervous system&#xD;
&#xD;
          -  Inflammatory disease or evolutive neoplasia and/or C reactive protein (CRP) upper than&#xD;
             10mg/L&#xD;
&#xD;
          -  Chronic use of alchohol and/or drug&#xD;
&#xD;
          -  Serious depression defined by Montgomery Asberg Depression Rating Scale (MADRS) score&#xD;
             higher than 18&#xD;
&#xD;
          -  Surgical or medical condition in the last 3 months&#xD;
&#xD;
          -  Long term treatment which could possibly interfere with inflammatory process&#xD;
             (especially the month before PET [18F]DPA-714 imaging).&#xD;
&#xD;
          -  Treatment by N-Methyl-D-Aspartate antagonist&#xD;
&#xD;
          -  Treatment by Minocycline&#xD;
&#xD;
          -  Treatment by benzodiazepine (especially the month before PET [18F]DPA-714 imaging)&#xD;
             (Zolpidem, zopiclone and loprazolam excepted)&#xD;
&#xD;
          -  Anomaly at neurological examination which is not a classical symptom&#xD;
&#xD;
          -  Contraindication to magnetic resonance imaging (RMI)&#xD;
&#xD;
          -  Florbetapir[18F] hypersensibility&#xD;
&#xD;
          -  Participation to an other experimental protocol with drug.&#xD;
&#xD;
          -  people under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent CAMUS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Tours</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>university hospital of Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Schmidt C, Wolff M, Weitz M, Bartlau T, Korth C, Zerr I. Rapidly progressive Alzheimer disease. Arch Neurol. 2011 Sep;68(9):1124-30. doi: 10.1001/archneurol.2011.189. Review.</citation>
    <PMID>21911694</PMID>
  </reference>
  <reference>
    <citation>Soto ME, Andrieu S, Arbus C, Ceccaldi M, Couratier P, Dantoine T, Dartigues JF, Gillette-Guyonnet S, Nourhashemi F, Ousset PJ, Poncet M, Portet F, Touchon J, Vellas B. Rapid cognitive decline in Alzheimer's disease. Consensus paper. J Nutr Health Aging. 2008 Dec;12(10):703-13.</citation>
    <PMID>19043645</PMID>
  </reference>
  <reference>
    <citation>Helmer C, Andrieu S, Pérès K, Orgogozo JM, Vellas B, Dartigues JF; REAL.fr Group. Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2007;23(3):168-74. Epub 2007 Jan 11.</citation>
    <PMID>17215578</PMID>
  </reference>
  <reference>
    <citation>Lo RY, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative. Vascular burden and Alzheimer disease pathologic progression. Neurology. 2012 Sep 25;79(13):1349-55. Epub 2012 Sep 12.</citation>
    <PMID>22972646</PMID>
  </reference>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>February 17, 2015</study_first_submitted>
  <study_first_submitted_qc>February 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>September 8, 2022</last_update_submitted>
  <last_update_submitted_qc>September 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET</keyword>
  <keyword>[18F]DPA-714</keyword>
  <keyword>cognitive decline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

